Senza is the only FDA-approved spinal cord stimulator with a specific indication to treat with painful diabetic neuropathy. The approval is specific to Nevro’s 10 kHz high-frequency therapy, according to a July 19 news release.
The system could allow painful diabetic neuropathy patients to discontinue long-term drug therapy and avoid “unwanted drug side effects,” said Frances Broyles, MD, medical director of diabetes/endocrinology and nutrition at Swedish Health Services in Seattle.
Nevro Chair, CEO and President Keith Grossman, MD, said he expects the new indication to be an “important driver of the long-term growth of our business for years to come.”
The company has initiated a commercial launch of the device.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
